Compare GHI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
| Metric | GHI | CRBU |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 173.3M | 192.4M |
| IPO Year | 1998 | 2021 |
| Metric | GHI | CRBU |
|---|---|---|
| Price | $5.30 | $2.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $10.50 | ★ $10.75 |
| AVG Volume (30 Days) | 57.3K | ★ 1.8M |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 22.93% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $85,389,766.00 | N/A |
| Revenue This Year | $273.95 | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | $529.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.71 | $1.04 |
| 52 Week High | $12.27 | $3.53 |
| Indicator | GHI | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 48.32 |
| Support Level | $5.04 | $1.75 |
| Resistance Level | $5.44 | $2.09 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 51.12 | 33.61 |
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.